EGFR and non-small cell lung carcinoma: Mobocertinib was granted accelerated approval in 2021; however, the confirmatory clinical trial investigating the use of mobocertinib in previously untreated patients with locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small cell lung cancer (EXCLAIM-2) Phase III trial showed no improvement in PFS versus platinum-based chemotherapy (median 9.6 months in both arms, HR 1.04).